6th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 20-22, 2025 | Orlando, Florida, USA
Neurotoxicity of Methamphetamine Use
Methamphetamine use can cause significant neurotoxicity, leading to long-term cognitive and behavioral impairments. This substance damages dopamine and serotonin systems in the brain, which are vital for mood regulation, reward processing, and motor function. Chronic methamphetamine exposure often results in oxidative stress and inflammation, further harming neural structures. Structural changes in brain regions, such as the prefrontal cortex and basal ganglia, are commonly observed, impairing decision-making and impulse control. These neurotoxic effects can persist even after prolonged abstinence, though some recovery may occur with time and therapeutic interventions. Addressing neurotoxicity through treatments like cognitive rehabilitation and antioxidant therapies is essential for improving the quality of life in affected individuals.
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
Denis Larrivee
University of Navarra, Spain
Scharbach Hugues
Paris University, France
Alphonsus Obayuwana
Triple-H Project LLC, United States
Malasri Chaudhery Malgeri
Recovery com, United States
Jana Furstova
Palacký University Olomouc, Czech RepublicSubmit your abstract Today
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States